Related Experiment Videos
Oncological applications of gene therapy
H S Pandha1, L A Martin, A S Rigg
1Department of Medical Oncology, St George's Hospital Medical School, Cranmer Terrace, London, SW17 ORE, UK. hpandha@sghms.ac.uk
Abstract:
Despite the rapid technological advances that continue to sustain the field of cancer gene therapy, few individual patients have benefited from the revolution so far. The plethora of clinical trials described confirms that each malignancy will have its own ideal strategy based on the associated molecular defects, and there has been rapid progress from this viewpoint. At the same time, there has been a renewed appreciation for the limitations to gene therapy, which include low efficiency of gene transfer, poor specificity of response and methods to accurately evaluate responses, and lack of truly tumor-specific targets at which to aim. As with all new therapies, we are climbing a steep learning curve in terms encountering treatment-related toxicities, as well as profound ethical and regulatory issues.
Insights
Cancer gene therapy advances show promise, but patient benefits remain limited due to challenges in gene transfer, specificity, and targeting. Overcoming toxicities and ethical issues is crucial for future progress.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Cancer gene therapy has seen rapid technological progress.
- Despite advances, few patients have directly benefited from this revolution.
- Individualized strategies based on molecular defects are emerging for various malignancies.
Purpose of the Study:
- To review the current state of cancer gene therapy.
- To highlight both the progress and limitations in the field.
- To discuss challenges including efficiency, specificity, and ethical considerations.
Main Methods:
- Review of existing literature and clinical trials in cancer gene therapy.
- Analysis of technological advancements and their clinical impact.
- Discussion of challenges and future directions.
Main Results:
- Significant progress has been made in understanding cancer's molecular basis for targeted therapy.
- Key limitations persist, including low gene transfer efficiency and poor response specificity.
- Accurate response evaluation and identification of tumor-specific targets remain challenging.
Conclusions:
- Cancer gene therapy requires tailored strategies for each malignancy.
- Overcoming technical hurdles like efficiency and specificity is essential.
- Addressing treatment-related toxicities and ethical/regulatory issues is critical for clinical translation.